Predicting bacterial resistance using the time inside the mutant selection window: Possibilities and limitations

International Journal of Antimicrobial Agents

Volumn 44, Issue 4, 2014, Pages 301-305

  Firsov, Alexander A ^a,b   Portnoy, Yury A ^a   Strukova, Elena N ^a   Shlykova, Darya S ^a   Zinner, Stephen H ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Fluoroquinolones; In vitro model; Resistant mutant enrichment

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG CONCENTRATION; ESCHERICHIA COLI; HYSTERESIS; IN VITRO STUDY; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; TIME INSIDE THE MUTANT SELECTION WINDOW; DRUG EFFECTS; GENETIC SELECTION; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION; STATISTICAL MODEL; THEORETICAL MODEL; TIME;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MODELS, THEORETICAL; MUTATION; SELECTION, GENETIC; TIME FACTORS;

EID: 84921924355     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.06.013     Document Type: Article

References (15)

1. X. Zhao, and K. Drlica Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies Clin Infect Dis 33 2001 147 156
2. A.A. Firsov, S.H. Zinner, and I.Y. Lubenko In vitro dynamic models as tools to predict antibiotic pharmacodynamics C.H. Nightingale, P.G. Ambrose, G.L. Drusano, T. Murakawa, Antimicrobial pharmacodynamics in theory and clinical practice 2nd ed. 2007 Informa Healthcare USA, Inc. New York, NY 45 78
3. A.A. Firsov, S.N. Vostrov, I.Y. Lubenko, K. Drlica, Y.A. Portnoy, and S.H. Zinner In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus Antimicrob Agents Chemother 47 2003 1604 1613
4. S.H. Zinner, I.Y. Lubenko, D. Gilbert, K. Simmons, X. Zhao, and K. Drlica Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing J Antimicrob Chemother 52 2003 616 622
5. D. Croisier, M. Etienne, L. Piroth, E. Bergoin, C. Lequeu, and H. Portier In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants J Antimicrob Chemother 54 2004 640 647
6. E. Gebru, M.-J. Choi, S.-J. Lee, D. Damte, and S.C. Park Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin J Med Microbiol 60 2011 1512 1522
7. A.A. Firsov, E.N. Strukova, D.S. Shlykova, Y.A. Portnoy, V.K. Kozyreva, and M.V. Edelstein Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations Antimicrob Agents Chemother 57 2013 4956 4962
8. S.K. Olofsson, L.L. Marcusson, P.K. Lindgren, D. Hughes, and O. Cars Selection of ciprofloxacin resistance of Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration J Antimicrob Chemother 57 2006 1116 1121
9. A.A. Firsov, M.V. Smirnova, E.N. Strukova, S.N. Vostrov, Y.A. Portnoy, and S.H. Zinner Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion Int J Antimicrob Agents 32 2008 488 493
10. J.J. Campion, P.J. McNamara, and M.E. Evans Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments Antimicrob Agents Chemother 48 2004 4733 4744
11. T. Homma, T. Hori, G. Sugimori, and Y. Yamano Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae Antimicrob Agents Chemother 51 2007 3810 3815
12. A.S. Kesteman, A.A. Ferran, A. Perrin-Guyomard, M. Laurentie, P. Sander, and P.-L. Toutain Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model Antimicrob Agents Chemother 53 2009 4740 4748
13. A.A. Firsov, S.N. Vostrov, A.A. Shevchenko, and G. Cornaglia Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model Antimicrob Agents Chemother 41 1997 1281 1287
14. A.P.R. Wilson, and R.N. Grüneberg Ciprofloxacin: 10 years of clinical experience 1997 Maxim Medical Oxford, UK
15. J. Cui, Y. Liu, R. Wang, W. Tong, K. Drlica, and X. Zhao The mutant selection window in rabbits infected with Staphylococcus aureus J Infect Dis 194 2006 1601 1608